medigraphic.com
Órgano Oficial del Instituto Nacional de Pediatría

2016, Number 4

<< Back Next >>

Acta Pediatr Mex 2016; 37 (4)

Pharmacokinetics of metformin in split tablets and in a liquid extemporaneous formulation for paediatrics, in healthy adult volunteers

Rivera-Espinosa L, Pérez-Guillé G, Chávez-Pacheco JL, Torres-Espíndola LM, Juárez-Olguín H, Alemón-Medina R

Language: Spanish
References: 27
Page: 191-203
PDF size: 504.59 Kb.


ABSTRACT

Background: Homemade fractions of metformin tablets to adjust paediatric doses are difficult to administer, unstable and yields variable doses. In this work, a liquid extemporaneous formulation of metformin, sweetened with 1% sucralose, is proposed.
Purpose: To determine the pharmacokinetics of the new formulation compared to the fractionated tablet in healthy adult volunteers and to demonstrate that it remains unaltered.
Methods: Randomised, crossed and longitudinal clinical trial, in 12 healthy adult volunteers, 7 males and 5 females (n=12), 24.3 ± 1.8 years, with BMI = 24.9 ± 2.5. Eight blood samples were obtained in Whatman 903χ2 cards at 0, 0.25, 0.5, 1, 2, 4, 8 and 12 hours after administration of 250 mg metformin. Extraction was made by direct precipitation with acetonitrile (ACN) and methanol. Detection was carried out by UPLC and tandem mass spectrometry. Mobile phase: 5 mM ammonium acetate and ACN (80:20; v/v), 0.25 mL/min, isocratically. Pharmacokinetics was determined using WinNonlin Pro 3.1 software and analysed by one-way ANOVA (p ≤ 0.05).
Results: The method was accurate, precise, selective and linear from 50 to 1000 ng/mL (r=0.9982). Samples were stable at 4°C for 17 hours and for 2 months at -80°C. The metformin formulation had a Cmax of 652 ng/mL and 550 ng/mL in the tablet. Tmax and ke were lower with the formulation (1.6 h vs. 1.8 h and 0.32 h-1 vs. 0.29 h-1). The AUC0-12 was virtually the same in both forms (F%=1.01).
Conclusions: The liquid formulation of metformin showed similar pharmacokinetics to the split tablet, but it additionally allows a more precise dose adjustment, ease of administration and uniformity of content.


REFERENCES

  1. Ventura EE, Davis JN, Alexander KE, Shaibi GQ, Lee W, Byrd-Williams CE, Toledo-Corral CM, Lane CJ, Kelly LA, Weigensberg MJ, Goran MI. Dietary intake and the metabolic syndrome in overweight Latino children. J Am Diet Assoc. 2008;108:1355-1359.

  2. Raj M, Kumar RK. Obesity in children and adolescents. Indian J Med Res. 2010;132(5):598–607.

  3. Aradillas-García C, Esperanza De la Cruz-Mendoza E, Torres- Ruvalcaba B, Montreal-Escalante E, Torres-Rodríguez L, Goldaracena-Azuara M. El impacto de la televisión sobre la prevalencia del síndrome metabólico en población infantil de San Luis Potosí. Bioquimia. 2008;33(1):10-18.

  4. Ioannides-Demos LL, Proietto J, McNeil JJ. Pharmacotherapy for Obesity. Drugs. 2005;65(10):1391-1418.

  5. Kanekara A, Sharma M. Pharmacological Approaches for Management of Child and Adolescent Obesity. J Clin Med Res. 2010;2(3):105-111.

  6. De Silva-Sanigorski A, Prosser L, Carpenter L, Honisett S, Gibbs L, Moodie M, Sheppard L, Swinburn B, Waters E. Evaluation of the childhood obesity prevention program Kids - 'Go for your life'. BMC Public Health. 2010;10:288.

  7. Lenzen S, Lortz S, Tiedge M. Effect of metformin on SGLT1, GLUT2, and GLUT5 hexose transporter gene expression in small intestine from rats. Biochemical Pharmacology. 1996;51:893-896.

  8. Fulgencio JP, Kohl C, Girard J, Pégorier JP. Effect of metformin on fatty acid and glucose metabolism in freshly isolated hepatocytes and on specific gene expression in cultured hepatocytes. Biochemical Pharmacology. 2001;62:439–446.

  9. Flores-Murrieta FJ, Aguilar-Cota ME, Camacho A, Reyes- García G, Herrera JE, Medina-Santillán R. Comparative bioavailability of two oral formulations manufactured in Mexico containing glyburide and metformin in diabetic patients. Proc. West. Pharmacol. Soc. 2003;46:82-84.

  10. Alemón-Medina R, Chávez-Pacheco JL, Rivera-Espinosa L, Ramírez-Mendiola B, García-Álvarez R, Sámano-Salazar C, Dávila-Borja VM. Extemporaneous formulations of metformin for pediatric endocrinology: physicochemical integrity, cytotoxicity of sweeteners, and quantitation of plasma levels. Clinical Therapeutics. 2015;37(8):1689-1702.

  11. Freemark M. Pharmacotherapy of childhood obesity.An evidence based conceptual approach. Diabetes Care. 2007;30(2):395-402.

  12. Zajicek A, Fossler MJ, Barrett JS, Worthington JH, Ternik R, Charkoftaki G, Lum S, Breitkreutz J, Baltezor M, Macheras P, Khan M, Agharkar S, MacLaren DD. A report from the pediatric formulations task force: perspectives on the state of child-friendly oral dosage forms. The AAPS Journal. 2013. DOI: 10.1208/s12248-0139511-5.

  13. Güthrie R and Susi A. A simple phenylalanine method for detecting phenylketonuria in large population of newborn infants. Pediatrics. 1963;32:338-343.

  14. Hoogtanders K, Van der J, Christiaans M, Edelbroek P, Van Hooff P, Stolk L. Therapeutic drug monitoring of tacrolimus with the dried blood spot method. J Pharm Biomed Anal. 2007;44(3):658-64.

  15. García A, Contreras L, P Ángeles C, Ramírez E, Trujillo J, Rivera L, Marcelín G. Pharmacokinetics of diphenylboroxazolidones of L-a-amino acids with activity on the CNS: quantification in rat DBS by UPLC-MS/MS. Bioanalysis. 2011;3(4):439-448.

  16. Filippos M, Theodoris G, Smith C, Wilson I. Metabolite profiles from dried biofluid spots for metabonomic studies using UPLC combined with oaToF-Ms. J Proteome Res. 2010;9(6):3328-3334.

  17. Barfield M, Spooner N, Lad R, Pary S, Fowles S. Application of DBS combined with HPLC-MS/MS for the quantification of acetaminophen in toxicokinetic studies. J Chromatogr B AnalytTechnol Biomed Life Sci 2008;87(1):32-37.

  18. Spooner N, Lad R, Barfield M. Dried blood spots as a sample collection technique for the determination of pharmacokinetics in clinical studies: considerations for the validation of a quantitative bioanalytical method. Anal Chem. 2009;81(4):1557-63.

  19. Baudette P and Bateman K. Discovery stage pharmacokinetics using dried blood spot. J Chromatogr B AnalytTechnol Biomed Life Sci. 2004;809(1):153-8. 51.

  20. Alemón-Medina R, Coria-Jiménez R, Rivera-Espinosa L, Ramírez- Mendiola B, García-Álvarez R, Juárez-Olguín H, Chávez-Pacheco JL. Physicochemical and Microbiological Stabilities of a Sweetened and Calorie-Free Metformin Extemporaneous Formulation for Pediatrics. Lat. Am. J. Pharm 2012;31(9):1253-60.

  21. Sánchez-Infantes D, Díaz M, López-Bermejo A, Marcos MV, de Zegher F, Ibáñez L. Pharmacokinetics of metformin in girls aged 9 years. Clinical Pharmacology 2011;50(11):735- 8.

  22. Norma Oficial Mexicana NOM-177-SSA1-2013. Diario Oficial de la Federación. 20 de septiembre de 2013. México. Consulted on 27th April 2015.

  23. Tollefsen KE, Nizzetto L, Huggett DB. Presence, fate and effects of the intense sweetener sucralose in the aquatic environment.Science of the Total Environment. 2012;438:510-516.

  24. Calzada-León R, Ruiz-Reyes ML, Altamirano-Bustamante N, Padrón-Martínez MM. Características de los edulcorantes no calóricos y su uso en niños. ActaPediatr Mex. 2013;34:141-153.

  25. Li W, Tse FLS. Dried blood spot sampling in combination with LC-MS/MS for quantitative analysis of small molecules. Biomedical Chromatography. 2010;24:49-65.

  26. Touw DJ, Neef C, Thomson AH, VinksAA.Cost-Effectiveness of Therapeutic Drug Monitoring Committee of the International Association for Therapeutic Drug Monitoring and Clinical Toxicology.Ther Drug Monit. 2005;27(1):10-7.

  27. Abu Ruz S, Millership J, McElnay J. The development and validation of liquid chromatography method for the simultaneous determination of metformin and glipizide, gliclazide, glibenclamide or glimperide in plasma. J Chromatography B. 2005;817:277-286




2020     |     www.medigraphic.com